The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Cedars-Sinai Medical Center to develop an innovative, minimally invasive liquid biopsy assay that can identify molecular subtypes of lethal prostate cancer. The $649,486 award will support the clinical translation of a large oncosome-based prostate cancer blood test to determine biomarkers of treatment response and track tumor phenotype evolution. Through this 5-year project, the researchers at Cedars-Sinai aim to perform analytical validation of the liquid biopsy technology, develop a multi-analyte assay to detect lethal prostate cancer, and assess the sensitivity and specificity of the assay in predicting clinical outcomes for patients with metastatic hormone-sensitive prostate cancer. The project leverages an extensive cohort of clinically annotated prostate cancer specimens to advance this minimally invasive diagnostic approach for lethal disease.
Generated 3/4/25, 4:10 AM